Member Info for paternostpauper

This RNS is not a standalone event — it’s the culmination of a strategy ValiRx has been quietly assembling for over a year. The pieces have been laid out methodically, and today another one clicks into place.

MARCH ‘25 -Val RNS’s a new Advisory Board chaired by Cathy Tralau Stewart, with two key veterinary figures: Dr Heather Wilson Robles, former President of the Veterinary Cancer Society and Dr Simon Wheeler, ex Novartis Ventures, specialising in veterinary investments. Since then, Dr Sheuli Porkess and Dr David Montgomery have joined, strengthening both scientific and commercial expertise. The AB was explicitly created to explore how ValiRx could leverage all its assets including human preclinical data for earlier access to the vet market.

JUNE - An RNS confirms Cytolytix and Omios to begin evaluating whether CLX001 enhances Omios’s next generation oncolytic viruses. The evaluation runs up to 12 months, after which Omios has an option to license the technology. In the June webinar, Mark explained that Omios’s tumour vasculature targeting virus could also be applied to dogs, specifically referencing Hemangiosarcoma (HSA), a metastatic cancer of the cells that line blood vessels eventually causing them to rupture - a major unmet need in veterinary oncology.

DECEMBER - In the Dec webinar, Mark was openly discussing developing CLX for the veterinary market, and confirmed that evaluation costs and the new SPV setup were ring fenced from the recent placing.

JANUARY ’26 -This LinkedIn post ahead of JPM reinforced the importance of Omios, with meetings lined up with CEO Aldo Pourchet as the evaluation approaches its June decision point: “Finally, there’s another great opportunity to showcase CLX and have meetings lined up with our partner Omios Bio so looking forward to catching up with CEO Aldo Pourchet.”

MARCH - Today’s RNS confirms “The Vet Oncology market was estimated at $1.58b in 2024 and is projected to hit nearly $4.86b by 2034”. Mark already has history here, with Volition selling a dog tumour test (Nu.Q) for $28m. At what valuation a cure?

Consistent with Mark’s 2026 SPV milestones, today’s RNS confirms that Val Animal Health aims for non dilutive funding, with specialist veterinary VC funds already approached. Taken together, the Advisory Board, Omios collaboration, webinar disclosures, and now the creation of Val Animal Health show a clear, deliberate strategy: accelerate development, derisk human programmes, open earlier revenue channels, and expand into a rapidly growing market. Today’s RNS isn’t a surprise - it’s the next logical piece of a well constructed plan.

Just done another little 590k top -up. Happy days. I'll explain why shortly.😁

Valirx has undergone a complete transformation under CEO Mark E, whose scientific depth, commercial acumen and 7% personal shareholding align him directly with shareholder success. He has built a compact, highly-skilled yet deeply specialised team, supported by an Advisory Board manned with industry experts.

Val is now preparing to expand into veterinary science and comparative oncology, with both areas identified as near term strategic opportunities. As always, every potential avenue is assessed through strict cost/benefit and timescale criteria. The company now operates a powerful, de risked model: a growing PDC biobank, multiple AI enabled capability partners, and SPVs that add value to compounds targeting some of the most aggressive cancers. CLX remains the flagship, negotiations ongoing with a major pharma and new patents filed with more to follow.

The Dominion alliance has identified 200 FDA approved non-oncology drugs showing anticancer activity, strengthening Val’s repurposing strategy. Val is at the forefront for grant applications, with Mark identifying immunotherapy and New Approach Methodologies as future opportunities long before the market did and even before US & UK legislation paved the way for reduced animal testing.

A major Ambrose deal signed, secured grants with further applications pending and SPV partnership/venture cap discussions are underway. With news on several projects now imminent, Val is entering a period of accelerated newsflow - backed by a confirmed runway into H2 minimum, with multiple opportunities for extension including £1.8m of warrants now within reach. Oh, and a CEO who is the company’s largest shareholder.

GLA, DYOR

“Cash runway is the length of time a PLC can continue operating before it runs out of cash, assuming its current rate of spending stays the same.”

Some posters on here still struggle with this. They believe that by artificially inflating costs they can paint a worse picture – unaware that cash runway already reflects actual outgoings. Even the £200k annual cost reduction is not relevant to that definition. I’m surprised Nick didn’t realise this; others, less so. That’s why Mark has been able to state publicly that the runway extends into H2 at minimum. That statement is based on current spend, not fiction. Other factors the doom posters conveniently ignore:

• should one or more of the current SPVs being targeted for partnering be successful, that entity becomes independently-financed and is removed from PLC costs.

• Any R&D tax credits, Inaphaea income, Dominion PredictRx revenue, UK / Int’l grants, or warrants exercised, will further improve the cash position.

In any of these scenarios, the runway would be extended and, in the case of the 0.5p warrants, well into 2027 — with 368m of those warrants representing a further £1.8m if exercised. All of these are runway extending events - none of them shorten it, yet together present multiple opportunities for extensions. Even the most creative accountant would struggle to compress that runway into March/April – unless of course, they had an agenda where fiction replaces reality.

GLA, DYOR

A PLC CEO’s obligation is simple: “To create sustainable long term value for shareholders while ensuring the company is legally compliant, financially sound, and strategically competitive.”

Against that benchmark, Mark E is entirely comfortable with how the business is progressing. There is no need - and no value - in rushing out RNSs simply to placate a handful of uninvested commentators. Unlike them, he is operating to a genuine strategic timeline where the objective is to see warrants actioned before the summer months. Their urgency stems from knowing that they only have weeks left before their fictitious runway becomes apparent to all.

As both CEO and major shareholder, Mark is indifferent to daily SP fluctuations. He isn’t trading the share; he is building the company. His objective is to protect his shareholders’ interests and grow long-term value – not to issue fluff announcements that will simply fan the flames. This year, Val has only issued one RNS - the McGill/IRICoR collaboration: the company’s first involving two global players, a 2nd generation later stage asset, multiple exit routes - all of which generate value for VAL, and conforms with Mark’s commitment to early monetisation.

He has confirmed the cash runway extends into H2 excluding R&D tax credits, warrants exercises, as yet unconfirmed Inaphaea income and grants submitted but pending. He cannot control the rants of a few uninvested posters who, once their “weeks left” narrative is disproven, simply invent a new one.

News is imminent on multiple fronts, highlighted in several earlier posts. Buy, sell, hold as you wish – but when the news lands, as it will, it is those holding the shares who will reap the rewards of Mark’s patience, discipline and long-term strategy.

GLA, DYOR

In June, the CEO said Val’s biggest opportunity would come from SPVs by “adding value” to existing compounds. Val now has Inaphaea, Blue Ribbon Bio, CytoLytix, and a further SPV announced as imminent. Mark has already reduced outgoings by £200k but by making SPVs self-financing entities, costs will reduce significantly - it comes from have a business-savvy CEO.

The Dec webinar set objectives (& milestones) for 2026: * Inaphaea (self-financing, admittedly overdue), * Val/Dom 3K (partner primary asset), * VAL201 (Grant or VC funded), * CLX formulation/ safety testing (partner &/or grant), * Pipeline expansion (evaluation & another SPV), * Decision time (StingRay, Dundee –“progressing well”, & Altus).

With a cash runway confirmed into H2, excluding R&D tax credits, additional revenue and UK/ international grants plenty of time for all the RNS updates now pending. Grants are likely to feature significantly as Val grows. The 12/8/24 RNS confirming his appointment advised “Mark is the Managing Director of OncoLytika Ltd, a UK based technology consultancy company with a successful track record of securing grant funding (close to €3 million in Eurostar funding)”. Only last Aug Mark announced a £250k Inaphaea grant – and since then both the US and UK have indicated priority will be given to companies adopting New Approach Methodologies (NAMs) in oncology projects. The UK Gov’t has gone even further, indicating a preference for academic/SME partnerships, putting Val in a very strong position.

The recent McGill / IRICoR RNS marks a first collaboration with global players and the Dec webinar confirmed CytoLytix partnering discussions are still ongoing with a major pharma. Val’s main focus is on cancer indications with huge annual markets: triple neg breast ($1.5Bn), prostate ($11.3Bn) & ovarian ($2.5Bn). With a patent cliff imminent for Big Pharma, significant acquisition/partnership activity of progressive SMEs is predicted to resolve the shortfall.

CEO, Mark bought 7% of the company – and he knows what’s coming! Nuff said.

Latest odds for next Val RNS:

CLX/201 patents -1/3 on, Altus licence confirmation - evens, new SPV/evaluation - 7/5, StingRay update - 2/1, ValDom lead asset partner - 3/1, Inaphaea income 5/1, Blue Ribbon VC announcement - 6/1, non-dilutive grant funding - 8/1, exclusive CLX early partnership -12/1, Nick S. TR1 - 10/1, Dundee pro-senescence update - 14/1, Ambrose/401 news 18/1, acquisition announcement – 25/1, Porky to replace Gerry D as CFO - 50000/1 #

Please note, all prices are subject to change.

# All Porky bets are currently suspended pending dope test.

Inaphaea has just released a short video re the collaboration with the Open University re prostate cancer. Funded by a Knowledge Transfer Voucher (RNS 7/8/25) this is yet another example of non-dilutive funding to progress assets using cutting edge technology that would otherwise be beyond the company’s reach.

https://lnkd.in/eXGeSPQq

“Important day in the calendar for patients, families and those of us working in the sector. The UK government has announced a directive to increase 5 year survival for cancer patients to 75% by 2035. This will take a a huge effort in terms of screening for early detection and diagnostics to allow curative surgery, improvements in surgical technique, such as robot assisted approaches and developments of affordable, accessible therapies.

VALIRX PLC and its subsidiaries, including Inaphaea BioLabs, Cytoltix and Blue Ribbon Bio are working hard to play our part in the discovery and development of next generation therapies. These include our novel oncolytic peptide program (targeting Triple Negative Breast Cancer), a first in class, non-genomic androgen receptor signalling inhibitor and a series of repurposed drugs from Inaphaea BioLabs 3K screen program. We work closely with leading academic institutions to source, assess and develop cutting edge approaches with pan cancer potential.

Our latest deal is with McGill University and IRICoR for a second generation RNA Helicase inhibitor (https://lnkd.in/ei5xwSpx)

Big shout out to our dedicated Inaphaea BioLabs team including Head of Scientific operations Melissa Barr, Lead Scientist - Translational Biology and Academic Collaboration, Amelia Hatfield and Lab tech Dylan Jones as well as VALIRX PLC's Director of Research, Michelle B.. There are currently 40 projects running in the labs at Inaphaea BioLabs covering our group therapeutic programmes and development of our non-animal based, New Approach Methodologies (NAMs) for drug screening with our unique bank of Patient Derived Cell models.

We couldn't do this without the support of our partners including TwinEdge Bioscience (Digital twin/Patient Avatars), ScreenIn3D (Lab on a chip platform), VoxCell (vascularised 3D tumour models), Spanios (organoid models), BioReperia (zebrafish models), Ignota Labs (in silico tox screening) and development partner Dominion Biotech as well as our shareholders.

It's been a hectic 18 months since I took over as CEO but we've focussed on refining our strategy, identifying high quality assets, building a strong team and expanding our capability partner network. We have a some major milestones set for 2026 and we look forward to being part of the solution and helping deliver patient benefits.”

Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding. Recent awards to UK microcap/small biopharmas include:

Momentous Therapeutics Ltd (immunotherapy) - £2m grant

Theolytics Ltd (ovarian cancer therapy) - £2m

Mestag Therapeutics Ltd (immunotherapy) - £1.5m

Revolver Therapeutics Ltd (peptide therapy) - £550k

Epitopea Ltd (breast cancer stromal cells / immunotherapy) - £500k

VacV Biotherapeutics Ltd (oncolytic viruses) - £500k

Antikor Biopharma Ltd (ovarian immunotherapy) - £500k

The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val’s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate — indications where new therapeutic approaches are urgently needed. This strengthens Val’s fit within the priority areas repeatedly backed by UK grant bodies.

The grants aren’t handouts; they’re strategic investments in the UK’s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability.

GLA, DYOR

To all the green bar brigade out there, you will get zero engagement from me. I have no desire to convert you and history lessons really don’t interest me. Feel free to post your drivel as all I can see is 6 consecutive green “This message has been filtered, please adjust your filters to view”. Han Solo couldn’t land a helicopter on your imaginary runway. 😁 😁 😁

To those actually invested, whether traders or otherwise, with all the news pending, the coming weeks and months are likely to be transformational.

GLA, DYOR

Grant schemes are increasingly geared towards small companies - when it comes to eligibility, size truly matters. Recent UK oncology research grants to SMEs reflect sustained investment in cutting edge cancer research, with Innovate UK and the Biomedical Catalyst programme providing much of the funding.

Recent awards to UK microcap/small biopharmas include:

Momentous Therapeutics Ltd (immunotherapy) - £2m grant

Theolytics Ltd (ovarian cancer therapy) - £2m

Mestag Therapeutics Ltd (immunotherapy) - £1.5m

Revolver Therapeutics Ltd (peptide therapy) - £550k

Epitopea Ltd (breast cancer stromal cells / immunotherapy) - £500k

VacV Biotherapeutics Ltd (oncolytic viruses) - £500k

Antikor Biopharma Ltd (ovarian immunotherapy) - £500k

The above awards show clear emphasis on immunotherapy, peptide based therapeutics, and oncolytic virus platforms. Val’s work not only aligns with these priority areas but also extends into difficult to treat cancers such as pancreatic, ovarian, triple negative breast, and prostate — indications where new therapeutic approaches are urgently needed. This strengthens Val’s fit within the priority areas repeatedly backed by UK grant bodies.

The grants aren’t handouts; they’re strategic investments in the UK’s future. A successful cancer therapy can deliver multi billion pound global sales and position the UK as a leader in next generation oncology. Regulators are now actively encouraging NAM adoption and funders are rewarding small oncology-focussed companies that have strong academic links. Valirx is exceptionally well-positioned to secure substantial grants, extend the cash runway and reinforce financial stability.

GLA, DYOR

Many of Mark’s presentations have highlighted the potential of grant-funding, with the 14/10/25 RNS confirming a £250k award. This followed a KTV Open Univ award only 2 months earlier and Mark has stated further grant applications are pending. The Inaphaea RNS (18/9/25) on the repurposing top10, noted “… discussions with potential licensees as well as an application for non-dilutive grant funding to support further development of these and other assets”. In addition to ongoing partnering discussions, CytoLytix updates invariably reference grant opportunities. As MD of OncoLytika, Mark has a strong history of securing significant grants, including Eureka Eurostar funding, demonstrating a proven ability to win competitive international grants.

Recent changes to UK and int’l grant frameworks — including the UK’s modernised Official Development Assistance (ODA) strategy, refreshed criteria, and new SME friendly collaboration rules — have opened funding routes that previously excluded early stage biopharma companies. These shifts prioritise oncology projects with demonstrable patient relevance, human relevant New Approach Methodologies (NAMs), and academia/SME partnerships, all of which align directly with Val’s revised operating model. The combination of Mark’s grant winning experience and the UK’s revised grant landscape creates a clear opportunity for Valirx as it enters its next phase of growth.

Good post UXM. Always entertaining to see trader Nick post again - his 63rd consecutive LSE post - and every one on Val. He might as well hang up a banner “roll up, roll up – bargain of a lifetime!” 🤣🤣🤣

Val has issued just one positive RNS since the placing, yet the SP has climbed 67% from those 0.23p lows. Even with 2 major holders dipping below the 3% threshold to facilitate some short-term trading, the SP still hovers near 0.4p.

Every day that passes without an RNS increases the likelihood of one the following day as multiple programs mature: CytoLytix patent updates, formulation decisions, Blue Ribbon/VAL201 partnering (by diluting the asset, not VAL plc), 3k repurposing update (top candidate partnering?), further grant updates (ME has strong history), next evaluation and SPV (confirmed in webinar), Inaphaea income (PredictRx/ PDC sales), updates on the Dundee/Queen Mary pro-senescence project and StingRay (decision imminent). The motherlode remains early partnering/grant funding for CLX, a 2026 milestone confirmed by the CEO in the recent webinar.

As the June anniversary nears, Omios have to decide whether they wish to exercise their option of a license agreement to continue using CLX tech. It looks promising as both Mark and Omios CEO Dr Aldo Pourchet had meetings arranged at the JPM in San Fran. More than once, Mark has referenced the Omios virus as an entry point to veterinary oncology due to its potential for treating canine HSA, while Dr Pourchet posted: “We are targeting triple negative breast cancers (CLX primary indication), all of which have the biomarker that makes them susceptible to our therapy. It’s our most advanced program” (Oct NYU interview). With multiple CytoLytix licenses up for grabs, Omios look set to start the ball rolling.

The decisive factor which totally undermines the detractors’ fearmongering is the financial position: a cash runway that extends till H2 excluding warrant income, R&D tax credits, grants, or additional Inaphaea income. That completely negates any March/April placing argument. Mind you, naysayers never let a few facts ruin their narrative.

GLA DYOR

@ spantrout - Great call. Valirx - 10m,50s in.

“A lot of return on that one!....DYOR but in all probability, if it’s going to have some game-changing news, then ….that would be 1.4p.”

Not sure of the news he is he is referring to? Maybe the new patents, partnering (CLX,201), repurposing top 10, StingRay, further grants, or expansion into veterinary oncology? Possibly it’s the the 2nd evaluation and new SPV or even the CEO buying 7% of the company. I suppose it could be that Mark E has recently been on stage presenting alongside some of the biggest names in pharma, or the fact the CEO has a history of delivering success (Nu.Q test sold for $26m).

!.4p is an interesting SP – that would not only see the 0.5p warrants in play but also the 1.3p warrants, easily extending the runway into 2027. Mind you realistically, a few easily pleased would exit for a quick 300%+ profit.

I guess the uninvested posting day and night trying to supress the SP hasn’t gone unnoticed either. Karma can be a wonderful thing!

Happy days

DYOR, GLA.

Seven consecutive “blocked” posts on a blue day tells me everything I need to know. LOL

The desperation of the naysayers knows no bounds – and the newsflow hasn’t even started yet.

I fear for the sanity of Porky and his parrots over the coming months. With an absolute minimum cash runway into July already confirmed and multiple RNS imminent, Porky could well self-check in to the local abattoir. The lorry reversing toward the sty, isn’t delivering feed. 🐷 🫨 ⚡ 🌭

Anyone for a bacon butty or sausage cob?

A lucrative VAL401 licensing deal was announced on 20/6/25: “ ValiRx will receive 576,000 ordinary shares in Ambrose with clinical and commercial milestone payments to be made to Valiseek totalling a value of up to £16 million plus royalties.” Valirx owns 54% of Valiseek.

Ambrose has a pipeline consisting of just TWO products: VAL401 (pancreatic cancer) and Renzapride (cystic fibrosis), both currently at phase 2 clinical.

Today, Ambrose announced two further additions to their already impressive team: Dr. Janette Thomas joins as Director of Manufacturing Operations and Wendy Richings-Barrow as Director of Regulatory Affairs. “These appointments reflect our continued focus on building a world class team to deliver solutions for patients with rare conditions with no approved treatments.”

The Ambrose team already had a strong backbone: Chairman, Toby Waterworth has been part of leadership teams in multiple life science companies that have generated close to $1 billion in shareholder value. CEO Dr Hazel Jones was formerly Chief of Staff for AstraZeneca’s Oncology R&D Leadership Team. Chief of Staff Virag Stephens an ex PMO Director at AZN and has strong fundraising expertise while Mike Webb led departments of up to 150 scientists in a 30-year career at GSK. Dr. Nick Meyers has 30 years’ experience as a Program Director.

In 2024, Ambrose was acknowledged by its peers when it won the Best Startup Biotech Company Award at the prestigious OBN Awards in London. Since then, it has grown significantly and confirmed it is exploring potential Middle-East listings. One of the partners on their webpage is SEHA (Abu Dhabi Health Services), a subsidiary of Pure-Health the largest integrated healthcare network in the UAE. (total assets $13B). Another partner is listed as Aparito, part of the Eli Lilly group.

As Ambrose strengthens its leadership and global partnerships, Valirx is strategically placed to benefit from every milestone achieved on the VAL401 journey.

“Valix is in discussions with several potential partners to progress CytoLytix, including a major pharma”. So, why is Mark, currently in California, continuing to promote the compound so actively both in the UK and overseas?

While it’s plausible a major pharma might seek exclusivity, the most realistic outcome is exclusive rights carved by territory, formulation, indication, or even species (human/veterinary)—leaving room for multiple, parallel deals outside that scope. Indication splits are historically used when partners specialise in different therapeutic areas (eg ovarian only). Geographic exclusivity is even more common. The TrX/201 deal eventually failed when Mark attempted to remove Taiwan from the original LOI. The veterinary angle highlighted in recent webinars reinforces that CLX spans markets no single pharma can cover, making a multi partner licensing model far more realistic than a single global licence.

There are numerous real world examples of multi partner licensing structures in biopharma:

TERRITORY - Immunex (Enbrel) / initially Amgen → US & Canada rights, then Wyeth (later Pfizer) → Europe + Rest of World rights

FORMULATION - Gilead (Tamiflu) / initially Roche → Oral formulation rights, then Hetero & Teva, → sublicenses for additional formulations

INDICATION - AstraZeneca (Lynparza) / Merck → initially Ovarian cancer rights, then subsequently obtained licenses for breast and pancreatic cancers.

Each example above shows one originator, no single-party lock in and multiple partners or deals to acquire different rights. With so many variables in play, it is increasingly clear that Valirx is preserving the same optionality for CytoLytix.

Mark is still promoting CytoLytix because he is targeting several partners – not just one. Everything suggests CLX is being shaped as a multi deal platform, with the first handshake simply opening the monetisation cycle -

Mark re JPM in San Fran - “I have meetings lined up with our partner Omios Biologics so looking forward to catching up with Aldo Pourchet (CEO).”

In the Omios RNS (3/6/25), the evaluation was “expected to run up to 12 months, after which Omios can exercise its license option to continue using Cytolytix technology.” Across both the June and Dec webinars, Mark emphasised CLX synergy with the Omios virus for potential to treat canine HSA, a clear signal that Omios sits firmly in the frame for a CLX licence.

Valirx’s revamped Advisory Board reinforces this direction, now with a notable weighting toward veterinary oncology and commercial expertise. The composition reflects a deliberate strategy to position CLX across both human and animal oncology. When your advisory structure is rebuilt around people who understand canine cancers, comparative oncology, and veterinary commercial pathways, it becomes clear Valirx is preparing for licensing routes across both human and veterinary markets. As a co-founder of VolitionRx, Mark transformed a human cancer test into a canine diagnostic test (Nu.Q) before negotiating a licencing deal with Heska for $26m. What price a cure?

Human and veterinary oncology operate in separate regulatory and commercial channels. Most major pharmas, inc. AZN, Roche, GSK, AbbVie do NOT have any vet divisions. Even those historically involved have spun off their animal health units (Pfizer → Zoetis, Eli Lilly → Elanco). By envisaging veterinary opportunities for CLX, Mark is implicitly confirming the compound won’t be a one partner asset; the split infrastructures required make multiple CytoLytix deals the only realistic outcome.

GLA, DYOR, AIMO

When Mark became CEO, ValirRx was effectively dormant - few assets in play, minimal Board investment and limited vision. He set about a major restructuring: rebuilding the team, reshaping the asset base and above all, resetting the mindset. Fast forward 17 months and Val is reborn. A microcap expanding into developing fields of oncology, yet every action taken has a cost/benefit analysis and timescale consideration. If concluded that a project cannot be monetised early, it is shelved or paused. Commercial decisions overrule all others.

Valirx is now plugged into some of the most advanced platforms in modern drug development:

• patient avatars (TwinEdge)

• microfluidics/3D tissue culture models (Screenin3D, Ignota & VoxCell)

• repurposing (Ignota, Altus & Dominion)

• personalised immunotherapy (PredictRx / Dominion)

• pro-senescence drugs (Dundee / Queen Mary Uni)

• Clickmer technology/HER2 protein (Apis Assay)

• LMTK3 kinase targeting (StingRay).

The most recent evaluation, a 2nd-gen RNA helicase inhibitor (McGill/IRICoR), brings Val into collaboration with major international research organisations.

Last year, Mark identified a shift away from animal-testing and moved early to establish capability partners supporting NAMs and cutting-edge AI. Recent US & UK Gov’t regulatory changes now actively favour such platforms with Europe to follow this year. Once again, Val anticipated this trend before much of the market.

Meanwhile, the Advisory Board has been upgraded from academics and towards industry experts who can provide insight into Big Pharma priorities and identify new commercial pathways such as in veterinary science - quicker to market while opening a parallel revenue path thru’ comparative oncology, further de risking the route to human oncology. Mark has also added a clause into evaluation agreements whereby if Val decides not to progress an asset eg StingRay, McGill/IRICoR, then Inaphaea retains the data and can still monetise should a 3rd party take the asset forward.

Val is no longer waiting for opportunity; it is engineering it.